Literature DB >> 10503654

The role of sex hormones in systemic lupus erythematosus.

R G Lahita1.   

Abstract

The disease systemic lupus erythematosus (SLE) is a complex one. One major clinical manifestation that relates to both cause and pathogenesis of all autoimmune diseases but specifically SLE is the sexual predilection for females. A consideration of mechanisms for this manifestation is the subject of this paper. The cytokine network is a major aspect of immune regulation and directly affected by sex steroids. The sexual dimorphism of the immune system relates to both organ-specific and general synthesis of sex steroids that are affected by and in turn affect cytokine profiles of T helper cells. There are also specific responses in cells from diseased patients that support the molecular activities of sex hormones on cells. Among these is the rise of calcineurin mRNA in SLE T cells in response to estrogen. Clinical research provides support for a more estrogenic environment in patients with SLE of both sexes. A preferential hydroxylation of estrone and increased oxidation of testosterone in patients with SLE maximizes the effects of estrogens on T cell functions. The effects of gonadotrophins like prolactin are discussed as stimulants of immune functions when elevated in SLE. Last, while the roles of exogenous estrogens on immune functions are known, the effects of such steroids alone or in combination with progestogens on SLE are not known. Investigation of both hormone replacement therapy and premenopausal hormone use are in progress.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10503654     DOI: 10.1097/00002281-199909000-00005

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  47 in total

1.  Contraceptives, pregnancy, and RA.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

Review 2.  New insights into the pathogenesis of systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; Christina G Katsiari; Yuang-Taung Juang; George C Tsokos
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

3.  Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.

Authors:  Bo Zheng; Xiang-Qing Yu; Warren Greth; Gabriel J Robbie
Journal:  Br J Clin Pharmacol       Date:  2016-03-04       Impact factor: 4.335

Review 4.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

Review 5.  Gender disparities in ocular inflammatory disorders.

Authors:  Hatice Nida Sen; Janet Davis; Didar Ucar; Austin Fox; Chi Chao Chan; Debra A Goldstein
Journal:  Curr Eye Res       Date:  2014-07-02       Impact factor: 2.424

6.  Prolactin modulates the naive B cell repertoire.

Authors:  Elena Peeva; Daniel Michael; James Cleary; Jeffrey Rice; Xian Chen; Betty Diamond
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

7.  Clinical features of Thai male lupus: an age-matched controlled study.

Authors:  Jitima Mongkoltanatus; Suparaporn Wangkaew; Nuntana Kasitanon; Worawit Louthrenoo
Journal:  Rheumatol Int       Date:  2007-09-06       Impact factor: 2.631

8.  Signal transducer and activation of transcription (STAT) 4beta, a shorter isoform of interleukin-12-induced STAT4, is preferentially activated by estrogen.

Authors:  Ebru Karpuzoglu; Rebecca A Phillips; Rujuan Dai; Carmine Graniello; Robert M Gogal; S Ansar Ahmed
Journal:  Endocrinology       Date:  2008-11-06       Impact factor: 4.736

Review 9.  Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus.

Authors:  E Kassi; P Moutsatsou
Journal:  J Biomed Biotechnol       Date:  2010-06-10

Review 10.  Review: Male systemic lupus erythematosus: a review of sex disparities in this disease.

Authors:  L-J Lu; D J Wallace; M L Ishimori; R H Scofield; M H Weisman
Journal:  Lupus       Date:  2009-11-27       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.